The Effect of Coenzyme Q10 on the Nervous Protection and Movement Disorders in Model of Mice Parkinson’s Disease induced by 6-HDOP
Subject Areas : Journal of Animal BiologyM. Azarshab 1 , J. Solati 2 , R. Hahikhani 3 , M. Rahnema 4 , M.R. Bigdeli 5
1 - Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran
2 - Department of Biology, Gohardasht Branch, Islamic Azad University, Karaj, Iran
3 - Department of Biology, North Tehran Branch, Islamic Azad University, Tehran, Iran
4 - Department of Biology, Zanjan Branch, Islamic Azad University, Zanjan, Iran
5 - Department of Biology, Faculty of Biological Scienves, Shahid Beheshti University, Tehran, Iran
Keywords: Coenzyme Q10, Mice, Parkinson, 6-Hydroxydopamine, Substantia Nigra,
Abstract :
Parkinson’s disease is one of the most common types of neurodegenerative diseases characterized by motor disorders such as slow motion, lack of movement, muscle stiffness, resting vibrations and facial masks. The main cause of the disease is the destruction of dopaminergic neurons in the compact part of the substantia nigra in the middle cerebrum, which is associated with a decrease in dopamine concentration at the terminals of corpus striatum. This study was conducted to investigate the effect of coenzyme Q10 on the 6-hydroxydopamine-induced animal model (PD). To create a mock-up model of Parkinson’s disease, 6-HDOP poison five μg/kg of mice body weight was injected into the Substantia nigra nucleus in adult NMRI mice. The accuracy of the Parkinson’s model in mice was confirmed using catalepsy and apomorphine-induced rotation tests. Immediately after surgery, the Parkinsonian mice were treated with water (solvent Q10) at doses of 25, 50, and 100 Coenzyme Q10 for two weeks and then subjected to behavioural tests, and the neurons of the substantia nigra nucleus were counted. The results indicated that treatment with Q10 significantly reduced the immobility time and Catalepsy, increased motor activity and decreased apomorphine rotation, indicating the protective effects of Coenzyme Q10 against Parkinson’s disease damage.
1. Aly N. 2012. Reno-protective efficiency of coenzyme Q10 on adriamycin-induced nephrotoxicity in rats. Journa of Applied Science Research, 8: 589.
2. Blandini F., Armentero M.T., Martignoni E., 2008. The 6-hydroxydopamine model: news from the past. Parkinsonism and Related Disorders, 14: S124-S129.
3. Blum D., Torch S., Lambeng N., Nissou M.F., Benabid A.L., Sadoul R., Verna J.M., 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Progress in Neurobiology, 65: 135-172.
4. Collins L.M., Toulouse A., Connor T.J., Nolan Y.M., 2012. Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology, 62(7): 2154-2168.
5. Crane F.L., 2001. Biochemical functions of coenzyme Q10. Journal of the American College of Nutrition, 20: 591-598
6. De Luca C., Kharaeva Z., Raskovic D., Pastore P., Luci A., Korkina L., 2012. Coenzyme Q10, vitamin E, selenium, and methionine in the treatment of chronic recurrent viral mucocutaneous infections. Nutrition, 28: 509-514.
7. Elbaz A., Bower J.H., Maraganore D.M., McDonnell, S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., Rocca W.A., 2002. Risk tables for parkinsonism and Parkinson's disease. Journal of Clinical Epidemiology, 55: 25-31.
8. Ferrari C.C., Tarelli R., 2011. Parkinson’s disease and systemic inflammation. Parkinson’s Disease, 2011: 436813.
9. Fujita M., Nishino H., Kumazaki M., Shimada S., Tohyama M., Nishimura T., 1996. Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Molecular Brain Research, 39(1-2):127-36.
10. Fujita M., Nishino H., Kumazaki M., Shimada S., Tohyama M., Nishimura T., 1996. Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Brain Research and Molecular Brain Research, 39(1-2): 127-36.
11. Hubble J.P., Cao T., Hassanein R., Neuberger J., Roller W., 1993. Risk factors for Parkinson's disease. Neurology, 43: 1693-1693.
12. Lenaz G., Fato R., Castelluccio C., Genova M., Bovina C., Estornell E., Valls V., Pallotti F., Castelli G.P., 1993. The function of coenzyme Q in mitochondria. The Clinical Investigator, 71: S66-S70.
13. Lin T.K., Liou C.W., Chen S.D., Chuang Y.C., Tiao M.M., Wang P.W., Chen J.B., Chuang J.H., 2009. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson’s disease. Chang Gung Medical Journal, 32: 589-599.
14. McCarthy S., Somayajulu M., Sikorska M., Borowy-Borowski H., Pandey S., 2004. Paraquat induces oxidative stress and neuronal cell death;neuroprotection by water-soluble Coenzyme Q10. Toxicology and Applied Pharmacology, 201(1): 21-31.
15. McGeer P.L., McGeer E.G., 2004. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism and Related Disorders, 10: S3-S7.
16. Ogura Y., Takagi K., Kawarada Y., Mizumoto R., 1996. Pathophysiological effect of hepatic ischemia and reperfusion after hepatectomy in dogs with obstructive jaundice, focusing on the effect of coenzyme Q10 and styrene-co-maleic acid superoxide dismutase. Journal of Gastroenterology, 31(3): 379-386.
17. Ostrowski R., Piotrowski P., Pańkowska T., Smiałek M., 1998. Evaluation of morphological changes after treatment with coenzyme Q10 (CoQ10) in endothelin-1 induced experimental ischemia in the rat. Folia Neuropathologica, 36: 185-188.
18. Overvad K., Diamant B., Holm L., Hølmer G., Mortensen S., Stender S., 1999. Coenzyme Q10 in health and disease. European Journal of Clinical Nutrition, 53: 764.
19. Prinssen E.P., Colpaert F.C., Koek W., 2002. 5-HT1A receptor activation and anti-cataleptic effects: High-efficacy agonists maximally inhibit haloperidol-induced catalepsy. European Journal of Pharmacology, 453(2-3): 217-221.
20 PubMed-NCBI Parkinsonism Relat Disord. 2012. 18suppl 1: S183-5.
21. PubMed-NCBI Neurourology Urodyn. 2009, 28(4): 339-42.
22. Savica R., Rocca W.A., Ahlskog J.E., 2010. When does Parkinson disease start? Archives of Neurology, 67: 798-801.
23. Schapira A.H., 2009. Neurobiology and treatment of Parkinson's disease. Trends in Pharmacological Sciences, 30: 41-47.
24. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., 2002. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of Neurology, 59: 1541-1550.
25. Sohet F.M., Neyrinck A.M., Pachikian B.D., de Backer F.C., Bindels L.B., Niklowitz P., 2009. Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice. Biochemical Pharmacology, 78(11): 1391-1400.
26. Storch A., Kaftan A., Burkhardt K., Schwarz J., 2000. 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. Journal of Neural Transmission, 107: 281-293.
27. Thoenen H., Tranzer J., 1968. Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn-Schmiedebergs Archiv für Pharmakologie und Experimentelle Pathologie, 261: 271-288.
28. Veldman B., Wijn A., Knoers N., Praamstra P., Horstink M., 1998. Genetic and environmental risk factors in Parkinson’s disease. Clinical Neurology and Neurosurgery, 100: 15-26.
29. Zhen R., Wenxiang D., Zhaokang S., Xinling G., Huiming H., Jingfeng L., Qing Y., Weizhong Z., Xiaoqing Y., 1994. Mechanisms of brain injury with deep hypothermic circulatory arrest and protective effects of coenzyme Q10. The Journal of Thoracic and Cardiovascular Surgery, 108: 126-133.